Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Filings indexed 719 across all filing types
Latest filing 2022-10-08 Director's Dealing
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-10-08 English
FORM 4 SUBMISSION
Director's Dealing
2022-10-05 English
FORM 4 SUBMISSION
Director's Dealing
2022-10-05 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 14, 2022, reporting the entry into a material definitive agreement related to an underwriting agreement for a public offering of common stock. It details the terms of the offering, the use of proceeds, and related legal opinions. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The document is an announcement of a capital raising event and financing activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 9039 characters, which is substantive and contains detailed information about the financing event, supporting a high confidence classification as CAP.
2022-09-16 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-09-16 English
FORM 4 SUBMISSION
Director's Dealing
2022-09-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.